FIGURE 5.

c-Src is involved in VEGF-C-mediated osteoclast bone resorption. A, OCPs from WT or Src^-/- mice were cultured on bone slices for 8 days and treated with RANKL, M-CSF, and VEGF-C. B, WT OCPs were cultured with M-CSF, RANKL, and VEGF-C with or without an Src inhibitor on bone slices for 8 days. The area of resorption pits on bone slices was assessed. Values are the means plus S.D. of four bone slices. ^*, p < 0.05 versus vehicle-treated cells or WT cells. #, p < 0.05 versus PBS-treated cells. C, WT OCPs were cultured with M-CSF and RANKL for 5 days to form osteoclasts. Cells were cultured in serum-free medium for 4 h and treated with VEGF-C or VEGFR3 agonist, VEGF-C (C156S), for 30 min. Expression of phospho-Src and total Src protein was determined by Western blot analysis.